$ACON

Aclarion (Nasdaq: ACON) published a CEO shareholder letter updating progress in H1 2026. The company cited 141% YoY and 71% sequential scan volume growth, U.K. reimbursement momentum, a U.S. Market Access Program with PRIA Healthcare, and continued CLARITY trial site expansion. It reported $16.3M cash and no debt as of June 30, 2026.

Aclarion (Nasdaq: ACON) said two abstracts on its Nociscan MR Spectroscopy platform were presented at the ASPN annual meeting. A real-world study workflow using Nociscan in 20 patients was described, and a case study reported 95% relief after basivertebral nerve ablation guided by Nociscan in a patient without classic Modic MRI changes.

Aclarion (Nasdaq: ACON) said Texas Spine Care Center will join its 300-patient, prospective randomized CLARITY trial evaluating Nociscan for surgical treatment of discogenic chronic low back pain. The primary endpoint is 12-month change in VAS back pain. Aclarion expects an initial internal readout and early interim results disclosure in Q4 2026.

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.

On May 29, analysts adjusted price targets across multiple stocks. Aclarion (ACON) was raised to $7.50 (Ascendiant). Autodesk (ADSK) saw mixed cuts and hikes, including Piper Sandler to $369 and Citigroup to $252. American Eagle (AEO) targets fell to as low as $17 (Barclays) and $19 (JPMorgan). Amazon (AMZN) rose to $320 (Truist).

Aclarion, Inc. has partnered with Source Healthcare to expand the availability of its Nociscan technology, a non-invasive diagnostic tool for chronic low back pain. This collaboration aims to gather real-world evidence comparing Nociscan to traditional diagnostic methods and supports Aclarion's strategy to build clinical evidence and increase adoption among healthcare providers and payers. The company recently secured $10.4 million in financing, boosting its cash reserves, and reported a significant increase in Nociscan scan volumes, alongside expanding insurance coverage in the UK.

Aclarion, Inc. has released its Q3 2023 10-Q report, detailing significant revenue growth primarily from the UK market and strategic business developments. The report highlights increased revenue to $18,942, an improved gross profit, and a net loss of $(1,706,294) due to expanded sales and marketing efforts. The company anticipates continued revenue growth and increased R&D expenses as it expands its insurance payor base and CLARITY Trial enrollment.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised Global-E Online Ltd ( NASDAQ:GLBE ) price target from $42 to $48.

Debt-free balance sheet with $13.3 million in cash as of today ( $15.11 per share fully diluted ) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. ...